The evidence landscape in precision medicine
暂无分享,去创建一个
Spencer Phillips Hey | Aaron S Kesselheim | Cory V Gerlach | Garrett Dunlap | Vinay Prasad | A. Kesselheim | V. Prasad | S. Hey | Cory V. Gerlach | Garrett Dunlap
[1] Vinay Prasad,et al. Precision oncology: origins, optimism, and potential. , 2016, The Lancet. Oncology.
[2] P. Queirolo,et al. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies , 2015, OncoTargets and therapy.
[3] M. Buyse,et al. Precision medicine needs randomized clinical trials , 2017, Nature Reviews Clinical Oncology.
[4] A. Kesselheim,et al. Countering imprecision in precision medicine , 2016, Science.
[5] J. Witte,et al. The Scientific Foundation for Personal Genomics: Recommendations from a National Institutes of Health–Centers for Disease Control and Prevention Multidisciplinary Workshop , 2009, Genetics in Medicine.
[6] K. Bloom,et al. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. , 2012, Archives of pathology & laboratory medicine.
[7] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[8] R. Porcher,et al. Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing , 2017, Scientific Reports.
[9] Heidi Ledford. Cutting-edge cancer drug hobbled by diagnostic test confusion , 2018, Nature.
[10] A. Kesselheim,et al. Research ethics for emerging trial designs: does equipoise need to adapt? , 2018, British Medical Journal.
[11] D. Ransohoff,et al. Biomarker studies: a call for a comprehensive biomarker study registry , 2011, Nature Reviews Clinical Oncology.
[12] Soonmyung Paik,et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.
[13] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[14] C. Weijer,et al. Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program , 2013, Trials.
[15] C. Compton,et al. Breaking a Vicious Cycle , 2013, Science Translational Medicine.
[16] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[17] J. Bozell. Breaking the vicious cycle. , 2007, Mental health today.
[18] G. Botti,et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[20] B. Dréno,et al. Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy? , 2014, The Journal of investigative dermatology.